(COO) The Cooper Companies, Inc. Company Overview

What does The Cooper Companies do?

The Cooper Companies, Inc. is a global medical device company listed on the Nasdaq Global Select Market under the ticker COO. Its business is organized around two operating units: CooperVision, which sells contact lenses and myopia-management products, and CooperSurgical, which sells fertility, women’s health, and selected surgical products and services. Cooper’s own company overview describes the group as focused on vision, women’s health, and surgical procedures, with corporate headquarters in San Ramon, California.

Why is Cooper important in healthcare devices?

Cooper is not a diversified hospital-equipment conglomerate. It is a focused specialty healthcare supplier with a large position in soft contact lenses and a second platform in fertility and women’s health. That focus matters because both markets combine recurring clinical use, professional recommendation, regulatory oversight, and product innovation. A student analyzing Cooper should therefore avoid treating revenue as ordinary consumer product sales. The company’s demand is routed through optometrists, eye-care practitioners, OB/GYN offices, hospitals, surgery centers, fertility clinics, and, in some areas, direct-to-consumer service channels.

How does CooperCompanies make money?

Cooper makes money by selling medical devices, lenses, services, and related healthcare products into specialist channels. Its FY2025 Form 10-K reports $2.744B of CooperVision net sales and $1.349B of CooperSurgical net sales. The economics are therefore led by CooperVision, but the strategic story is broader: CooperVision contributes most revenue and operating income, while CooperSurgical gives the company exposure to fertility, women’s health, and selected surgical categories.

Which revenue stream is the core engine?

CooperVision is the core earnings engine because specialty lenses can carry high gross margins, benefit from recurring replacement cycles, and depend on professional fitting rather than purely price-driven shelf competition. Cooper’s 2025 segment data show CooperVision generated about 67.0% of consolidated net sales but a much larger share of operating income before corporate costs. CooperSurgical is strategically important because it addresses higher-acuity women’s health and fertility markets, but its reported FY2025 operating margin was much lower due to write-offs, severance, amortization, and acquisition-related complexity.

How do the two operating models differ?

Which segments and products matter most for growth?

The fastest way to understand Cooper is to separate category growth from mix quality. A dollar of toric or multifocal lens sales is not the same strategic signal as a dollar from an older spherical lens line. Similarly, fertility growth carries a different risk profile than an office or surgical device sale because it depends on clinic volumes, laboratory trust, and service quality.

What does CooperVision’s product mix say?

In FY2025, CooperVision’s toric and multifocal products generated $1.351B, while sphere and other products generated $1.393B. That near-even split is important: Cooper is not only selling basic correction, but also more specialized products that require parameter breadth and fitting support. The company also reports MiSight as a myopia-control product, with FDA approval in 2019 for children aged 8 to 12 at initiation and subsequent approvals in China and Japan. The strategic point is that CooperVision’s growth depends on premium category penetration, not only total lens wearer growth.

What does CooperSurgical’s category mix say?

CooperSurgical generated $824.0M from office and surgical products and $524.6M from fertility in FY2025. The Q2 FY2026 release then showed fertility revenue up 13% reported and 10% organically, versus 4% organic growth for office and surgical. That mix gives CooperSurgical a visible growth vector, but it also raises the importance of quality systems and reputation because fertility-related products operate in a highly sensitive clinical setting.

What does CooperCompanies’ latest quarter show?

The latest official performance signal is fiscal Q2 2026, the quarter ended April 30, 2026. Cooper reported record quarterly revenue of $1.082B, up 8% as reported and 5% organically, in its Q2 FY2026 earnings release. The headline revenue signal was strong, but GAAP earnings were distorted by a major litigation-related charge tied to a December 2023 CooperSurgical voluntary product recall.

Why did GAAP profit turn negative?

GAAP operating margin was negative 3% in Q2 FY2026, compared with 18% a year earlier, because SG&A included a $271.6M net pre-tax litigation-related charge. The charge consisted of $324.1M of accrued litigation liabilities partly offset by $52.5M of expected insurance recoveries. That is why a reader should separate operating execution from legal-cost recognition. Non-GAAP operating income was $297.2M, while GAAP operating loss was $31.0M for the quarter.

How did CooperCompanies become strategically important?

Cooper’s history matters because the present company is the result of focus, category expansion, and acquisition-led portfolio building rather than a single blockbuster product. The company’s investor FAQs state that Cooper was incorporated in Delaware in March 1980 as CooperVision, Inc. and adopted its present name on June 22, 1987. That evolution foreshadowed the eventual two-platform structure: CooperVision as the lens engine and CooperSurgical as the women’s health and fertility platform.

1. 1980
   Incorporated as CooperVision, Inc.; the identity began with vision care, which still produces the majority of revenue and operating income.
2. 1987
   Adopted The Cooper Companies name, making room for a broader medical-device portfolio beyond vision.
3. 2007-2018
   Robert Weiss’s CEO tenure pushed CooperVision into daily disposable and silicone hydrogel lenses, helping market share rise from about 15% to more than 22% according to company leadership materials.
4. 2019
   MiSight received U.S. FDA approval for slowing myopia progression in children aged 8 to 12 at initiation, giving Cooper a differentiated pediatric myopia platform.
5. 2021-2025
   MiSight approvals in China and Japan extended the myopia-management opportunity in large international markets.
6. 2024
   Acquisitions and integration activity in CooperSurgical expanded the portfolio but also added amortization and integration complexity.
7. 2026
   The company moved to resolve substantially all claims connected with the December 2023 fertility media recall while reaffirming its FY2026-FY2028 free-cash-flow objective.

What strategic tension does this history create?

The tension is that CooperVision looks like a durable, scaled, high-margin specialist, while CooperSurgical looks more acquisition-shaped, procedure-linked, and litigation-sensitive. That does not make CooperSurgical unattractive; fertility and women’s health can be compelling categories. But it means researchers should analyze Cooper as two connected but different businesses rather than one uniform medical-device story.

What gives CooperCompanies a competitive advantage?

Cooper’s advantage is built from product specialization, practitioner trust, manufacturing capability, and channel relevance. In contact lenses, Cooper says companies compete on differentiated products, efficient manufacturing, a wide range of lens parameters, and customer and professional services. That explains why CooperVision’s SKU breadth and fit success matter: the eye-care practitioner is not merely buying a commodity lens, but choosing a product that must work for the patient’s prescription, comfort, modality, and follow-up needs.

Why does product breadth matter in contact lenses?

CooperVision competes in spherical, toric, and multifocal categories, and its 2025 annual report describes a broad range of lens parameters. This is not a cosmetic detail. A broad parameter range can improve the probability that practitioners find a lens that fits, corrects vision effectively, and keeps the patient in the modality. That is a resource-based advantage: it combines product development, manufacturing precision, practitioner education, and distribution reliability.

Where is the moat less certain?

The moat is less certain where products are acquired, reimbursement-sensitive, or exposed to direct competition from larger healthcare companies. CooperSurgical’s fertility and women’s health categories require innovation and quality, but the margin base is lower than CooperVision’s, and recall-related litigation shows that trust can become a financial issue. That is why Cooper’s competitive advantage is strongest in its scaled lens franchise and more conditional in the surgical and fertility portfolio.

Who are CooperCompanies’ main competitors and how is it positioned?

The competitive map differs sharply by segment. In the 2025 annual report, CooperVision names Johnson & Johnson Vision Care, Alcon, and Bausch + Lomb as large contact-lens competitors, while CooperSurgical competes against fertility, women’s health, medical-device, IUD, genomics, cord-blood, and service providers. Cooper’s filing emphasizes that rivals may have greater financial resources, larger R&D budgets, larger sales forces, greater market penetration, and larger manufacturing volumes.

How does CooperVision defend its position?

CooperVision’s defense is specialization rather than pure scale. The company competes with a full silicone hydrogel product set, customized parameters, and practitioner services. It also benefits from long-term shifts toward daily disposable lenses, specialty correction, and myopia management. However, larger vision competitors can cross-sell eye-care products and may have broader marketing and manufacturing resources, so Cooper’s differentiation must translate into fitting success and practitioner loyalty.

Which rivals pressure each platform?

How financially strong is CooperCompanies?

Financially, Cooper has the characteristics of a high-gross-margin healthcare device company with meaningful debt and a currently important legal overhang. The fiscal 2025 annual base showed $4.092B of net sales, $2.682B of gross profit, $682.9M of operating income, $374.9M of net income, and $796.1M of operating cash flow. But the latest quarter showed how quickly one product-liability issue can distort GAAP profitability.

What do margins and cash flow reveal?

The key margin line is not simply consolidated net margin. CooperVision’s FY2025 operating income was $729.6M, equal to 26.6% of CooperVision net sales, while CooperSurgical’s FY2025 operating income was $43.4M, equal to 3.2% of CooperSurgical net sales. That gap is the most important financial driver in the article. It means a small change in CooperVision growth or margin has a larger valuation impact than a similar revenue change in CooperSurgical, unless CooperSurgical’s profitability improves materially.

How does capital allocation affect the story?

Cooper ended the regular semiannual dividend in December 2023 and shifted capital allocation toward cash generation, debt capacity, acquisitions, and buybacks. In FY2025, the company repurchased 4.1M shares for $290.1M at a weighted average price of $69.30. In Q2 FY2026 it repurchased approximately 174,000 shares for $13.1M at an average price of $75.84, with $860.8M remaining under the program. That buyback authorization is meaningful, but the stronger valuation input is still free cash flow after capex, litigation cash costs, and debt service.

Who owns CooperCompanies stock and why does governance matter?

Cooper is not a founder-controlled dual-class company. The latest 2026 proxy statement indicates one share, one vote and about 195.1M shares outstanding on the February 9, 2026 record date. Control is therefore institutionally influenced rather than founder dominated. Large passive and active institutional holders matter because they can affect board accountability, executive compensation scrutiny, and support for capital-allocation decisions.

Which shareholders are most visible in the proxy?

What does governance signal about strategy?

Governance signals a conventional public-company structure: a separated board chair and CEO, independent directors, board committee oversight, and share-based incentive alignment. The proxy also frames strategic priorities around resilient market share gains, premium products and innovation, continuous improvement, strong cash generation, share repurchases, and the OneCooper initiative. For researchers, the main governance question is whether management can convert those priorities into consistent free cash flow while resolving CooperSurgical’s legal and margin issues.

Which KPIs matter most for CooperCompanies?

Cooper’s KPIs should be chosen to match the two-segment economics. For CooperVision, the useful metrics are organic growth, category mix, geography, gross margin, manufacturing capacity, and specialty-lens adoption. For CooperSurgical, researchers should track fertility growth, office and surgical growth, quality and recall costs, amortization, and operating margin. At the consolidated level, free cash flow, debt, buybacks, R&D, and litigation accruals matter more than headline EPS in a noisy period.

How should students connect KPIs to valuation?

A DCF model for Cooper should not begin with a single consolidated growth rate. It should separate CooperVision revenue growth, CooperSurgical revenue growth, segment margins, cash taxes, capex, working capital, and legal cash outflows. A simple formula helps: free cash flow equals operating cash flow minus capital expenditures. In Q2 FY2026, that was $182.8M minus $86.4M, or $96.4M. The ratio to revenue was about 8.9% for the quarter, but that single quarter should be compared against the company’s longer-term free-cash-flow objective and FY2025 operating cash flow of $796.1M.

What risks could weaken CooperCompanies’ outlook?

Cooper’s risk profile is company-specific. The most visible current risk is the product-related litigation tied to the CooperSurgical fertility media recall, but it is not the only issue. The annual report also highlights competition, pricing pressure, supply-chain constraints, materials availability, product innovation, regulatory approval and certification delays, reimbursement, cybersecurity, international operations, foreign currency, tariffs, debt, and acquisition integration. These are not abstract boilerplate risks; several connect directly to current financial lines.

Which opportunities offset those risks?

The opportunity set is still meaningful. CooperVision can benefit from specialty lens penetration, myopia management, international growth, and manufacturing efficiencies. CooperSurgical can benefit from fertility demand, product portfolio integration, and better margin discipline. Management’s FY2026 guidance calls for total revenue of $4.285B to $4.321B, CooperVision revenue of $2.883B to $2.908B, CooperSurgical revenue of $1.402B to $1.414B, and non-GAAP EPS of $4.58 to $4.66. The company also reaffirmed a long-term free-cash-flow objective exceeding $2.2B for FY2026 through FY2028.

What is the key takeaway from CooperCompanies analysis?

CooperCompanies is best understood as a two-platform specialty medical-device company: a scaled, high-margin contact-lens franchise and a more complex women’s health and fertility platform. CooperVision explains most of the financial strength because it combines recurring use, professional recommendation, product breadth, global channels, and premium lens categories. CooperSurgical adds growth exposure in fertility and women’s health, but it also introduces lower reported margins, acquisition integration, amortization, quality sensitivity, and the current litigation overhang.

What should a researcher monitor next?

• Whether CooperVision organic growth stays near or above the Q2 FY2026 rate of 4%.
• Whether toric, multifocal, daily disposable, silicone hydrogel, and myopia-management products keep improving mix quality.
• Whether CooperSurgical fertility growth converts into higher segment operating margin.
• Whether litigation accruals, insurance recoveries, and cash settlements evolve better or worse than the Q2 FY2026 balance sheet suggested.
• Whether operating cash flow and capex support the FY2026-FY2028 free-cash-flow target above $2.2B.
• Whether buybacks remain opportunistic after debt, acquisition, legal, and reinvestment requirements.

For valuation work, Cooper’s most important assumptions are not exotic. They are CooperVision organic growth, consolidated gross margin, CooperSurgical margin recovery, capex intensity, working-capital discipline, litigation cash timing, and the discount rate applied to a healthcare device company with recurring demand but real legal and regulatory risk. The official Q2 FY2026 Form 10-Q filing page and the company’s annual reports and proxy statements are the best primary documents to keep updated as those assumptions change.